Klebsiella Pneumoniae Infections Market 2026

February 2025 | 200 pages | ID: KA8AED140C21EN
DataM Intelligence

Abstracts

The Klebsiella Pneumoniae Infections Market was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Klebsiella Pneumoniae Infections Market.

This report delivers a comprehensive overview of the Klebsiella Pneumoniae Infections Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Klebsiella Pneumoniae Infections Market. The Klebsiella Pneumoniae Infections Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

Klebsiella Pneumoniae Infections Market Scope:

By Infection Type

• Pneumonia
• Urinary Tract Infections (UTIs)
• Bloodstream Infections
• Intra-Abdominal Infection
• Wound Infections

By Drug Class

• Beta-Lactams
• Aminoglycoside
• Quinolones
• Cephalosporins
• Carbapenems

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Key Players

• Pfizer Inc.
• Novartis AG
• AdvaCare Pharma
• Merck & Co., Inc.
• Ortho-McNeil-Janssen Pharmaceuticals, Inc.
• Teva Pharmaceuticals USA, Inc.
• Aurobindo Pharma Colombia
• Par Pharmaceutical
• AbbVie
• Actavis

Major Highlights

This report delivers a comprehensive overview of the Klebsiella Pneumoniae Infections Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Klebsiella Pneumoniae Infections Market. The Klebsiella Pneumoniae Infections Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Infection Type
3.2. Snippet by Drug Class
3.3. Snippet by Distribution Channel
3.4. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Advancements in Treatment Options for Managing Klebsiella Pneumoniae Infections
    4.1.1.2. The Rising Number of Clinical Trials Focused on Addressing Klebsiella Pneumoniae Infections
    4.1.1.3. Rapid Prediction of Multidrug-Resistant Klebsiella Pneumoniae through Deep Learning Analysis of SERS Spectra
  4.1.2. Restraints
    4.1.2.1. Limited Treatment Options for KPC-Producing Klebsiella Pneumoniae
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Patent Analysis
5.7. Russian-Ukraine Conflict Analysis
5.8. DMI Opinion

6. COVID-19 ANALYSIS

6.1. Analysis of COVID-19
  6.1.1. Scenario Before COVID
  6.1.2. Scenario During COVID
  6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. BY INFECTION TYPE

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  7.1.2. Market Attractiveness Index, By Infection Type
7.2. Pneumonia*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Urinary Tract Infections (UTIs)
7.4. Bloodstream Infections
7.5. Intra-Abdominal Infection
7.6. Wound Infections

8. BY DRUG CLASS

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  8.1.2. Market Attractiveness Index, By Drug Class
8.2. Beta-Lactams*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  8.2.3. Clavulanic Acid
  8.2.4. Sulbactam
  8.2.5. Tazobactam
  8.2.6. Avibactam
  8.2.7. Vaborbactam
8.3. Aminoglycoside
  8.3.1. Gentamicin
  8.3.2. Tobramycin
  8.3.3. Amikacin
  8.3.4. Streptomycin
  8.3.5. Others
8.4. Quinolones
  8.4.1. Ciprofloxacin (Cipro)
  8.4.2. Levofloxacin
  8.4.3. Moxifloxacin
  8.4.4. Ofloxacin
  8.4.5. Norfloxacin
  8.4.6. Gemifloxacin
  8.4.7. Others
8.5. Cephalosporins
  8.5.1. Ceftriaxone
  8.5.2. Cefotaxime
8.6. Carbapenems
  8.6.1. Imipenem/cilastatin
  8.6.2. Meropenem
  8.6.3. Doripenem
  8.6.4. Ertapenem

9. BY DISTRIBUTION CHANNEL

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies

10. BY REGION

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  10.1.2. Market Attractiveness Index, By Region
10.2. North America
  10.2.1. Introduction
  10.2.2. Key Region-Specific Dynamics
  10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.2.6.1. U.S.
    10.2.6.2. Canada
    10.2.6.3. Mexico
10.3. Europe
  10.3.1. Introduction
  10.3.2. Key Region-Specific Dynamics
  10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.3.6.1. Germany
    10.3.6.2. UK
    10.3.6.3. France
    10.3.6.4. Italy
    10.3.6.5. Rest of Europe
10.4. South America
  10.4.1. Introduction
  10.4.2. Key Region-Specific Dynamics
  10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.4.6.1. Brazil
    10.4.6.2. Argentina
    10.4.6.3. Rest of South America
10.5. Asia-Pacific
  10.5.1. Introduction
  10.5.2. Key Region-Specific Dynamics
  10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.5.6.1. China
    10.5.6.2. India
    10.5.6.3. Japan
    10.5.6.4. Australia
    10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
  10.6.1. Introduction
  10.6.2. Key Region-Specific Dynamics
  10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. COMPANY PROFILES

12.1. Pfizer Inc. *
  12.1.1. Company Overview
  12.1.2. Product Portfolio and Description
  12.1.3. Financial Overview
  12.1.4. Key Developments
12.2. Novartis AG
12.3. AdvaCare Pharma
12.4. Merck & Co., Inc.
12.5. Ortho-McNeil-Janssen Pharmaceuticals, Inc.
12.6. Teva Pharmaceuticals USA, Inc.
12.7. Aurobindo Pharma Colombia
12.8. Par Pharmaceutical
12.9. AbbVie
12.10. Actavis (*LIST NOT EXHAUSTIVE)

13. APPENDIX

13.1. About Us and Services
13.2. Contact Us